Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2002; 40:175-181
© 2002 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ueno, M.
Right arrow Articles by Yamaguchi, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ueno, M.
Right arrow Articles by Yamaguchi, I.

A combination of oral endothelin-areceptor antagonist and oral prostacyclinanalogue is superior to each drug alone inameliorating pulmonary hypertension in rats

Michihiko Ueno, MD, PhD*, Takashi Miyauchi, MD, PhD*,*, Satoshi Sakai, MD, PhD*, Rikako Yamauchi-Kohno, PhD{ddagger}, Katsutoshi Goto, PhD{dagger} and Iwao Yamaguchi, MD, PhD*

* Cardiovascular Division, Department of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba, Tsukuba, Ibaraki, Japan
{dagger} Department of Pharmacology, Institute of Basic Medical Sciences, University of Tsukuba, Tsukuba, Ibaraki, Japan
{ddagger} Discovery Research Laboratory, Tanabe Seiyaku Co. Ltd., Toda, Saitama, Japan



View larger version (30K):

[in a new window]
 
Figure 1 Changes in the ratio of the minor axis (a) of left ventricle (LV) to the major axis (b) of the LV, an index of pulmonary hypertension (PH), in the parasternal short-axis view of the LV by two-dimensional echocardiography. The view was obtained at the level of the papillary muscle. It was evaluated on days 1, 7, 14 and 19 after the start of treatment. Control group (open circles, n = 12); PH group (solid circles, n = 17); PH + TA group (open squares, n = 18); PH + BPS group (solid squares, n = 13); and PH + TA + BPS group (open diamonds, n = 18). *p < 0.05 vs. Control group. §p < 0.05 vs. PH group. #p < 0.05 vs PH + TA + BPS group. p < 0.05 vs. baseline value of each group on day 1. Data are presented as the mean value ± SE. BPS = beraprost sodium; PH = pulmonary hypertension; RV = right ventricle; TA = TA-0201.

 


View larger version (20K):

[in a new window]
 
Figure 2 Right ventricular systolic pressure (left) and Pp/Ps ratio (right) in the Control group (n = 12), PH group (n = 17), PH + TA group (n = 18), PH + BPS group (n = 13) and PH + TA + BPS group (n = 18). *p < 0.05 vs. Control group. §p < 0.05 vs. PH group. #p < 0.05 vs. PH + TA + BPS group. Each column and bar represents the mean value ± SE. BPS = beraprost sodium; PH = pulmonary hypertension; TA = TA-0201.

 


View larger version (20K):

[in a new window]
 
Figure 3 Ratio of right ventricular (RV) wet weight to BW (left) and ratio of RV wet weight to left ventricular (LV) wet weight (right) in the Control group (n = 12), PH group (n = 17), PH + TA group (n = 18), PH + BPS group (n = 13) and PH + TA + BPS group (n = 18). *p < 0.05 vs. Control group. §p < 0.05 vs. PH group. #p < 0.05 vs. PH + TA + BPS group. Each column and bar represents the mean ± SE. BPS = beraprost sodium; PH = pulmonary hypertension; TA = TA-0201.

 


View larger version (23K):

[in a new window]
 
Figure 4 Ratio of expression level of beta-myosin heavy chain (MHC) messenger ribonucleic acid (mRNA) to alpha-MHC mRNA in the right ventricle in the Control group (n = 12), PH group (n = 17), PH + TA group (n = 18), PH + BPS group (n = 13) and PH + TA + BPS group (n = 18). A typical example of the reverse transcription (RT)-polymerase chain reaction (PCR) product in each group is also shown. *p < 0.05 vs. Control group. §p < 0.05 vs. PH group. #p < 0.05 vs. PH + TA + BPS group. Each column and bar represents the mean value ± SE. BPS = beraprost sodium; PH = pulmonary hypertension; TA = TA-0201.

 


View larger version (93K):

[in a new window]
 
Figure 5 Photomicrographs of the pulmonary arteries in the Control group (A), PH group (B) and PH + TA + BPS group (C). Histologic examination of the lung showed a marked increase in pulmonary arterial medial wall thickening in the PH group. The increase in the thickening was attenuated in the PH + TA + BPS group. Each section was stained with Azan (x520). BPS = beraprost sodium; PH = pulmonary hypertension; TA = TA-0201.

 


View larger version (16K):

[in a new window]
 
Figure 6 Ratio of medial wall thickness to the external diameter of the pulmonary arteries of rats in the Control group (n = 12), PH group (n = 17), PH + TA group (n = 18), PH + BPS group (n = 13) and PH + TA + BPS group (n = 18). Pulmonary arteries with an external size of about 50 µm were chosen. *p < 0.05 vs. Control group. §p < 0.05 vs. PH group. #p < 0.05 vs. PH + TA + BPS group. Each column and bar represents the mean value ± SE. BPS = beraprost sodium; PH = pulmonary hypertension; TA = TA-0201.

 




 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement